Theravance Biopharma News

Theravance Biopharma Analyst Ratings

BenzingaApr 12 07:36 ET

Balancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharma

TipRanksFeb 26 21:55 ET

Positive Financial Trajectory and Future Prospects Prompt Buy Rating for Theravance Biopharma

TipRanksNov 10, 2023 06:28 ET

Promising Growth and Profitability Prospects: A Buy Rating for Theravance Biopharma

TipRanksNov 8, 2023 06:34 ET

Hold Rating on Theravance Biopharma Amidst Steady Growth and Positive Future Expectations

TipRanksNov 8, 2023 00:37 ET

Analysts Are Bullish on These Healthcare Stocks: Theravance Biopharma (TBPH), BioMarin Pharmaceutical (BMRN)

TipRanksNov 2, 2023 01:43 ET

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target

BenzingaAug 8, 2023 06:15 ET

Theravance Biopharma Analyst Ratings

BenzingaAug 8, 2023 06:13 ET

SVB Securities Remains a Buy on Theravance Biopharma (TBPH)

TipRanksMay 11, 2023 12:46 ET

HC Wainwright Adjusts Price Target on Theravance Biopharma to $20 From $19, Keeps Buy Rating

MT NewswiresMay 9, 2023 09:54 ET

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $20

BenzingaMay 9, 2023 06:41 ET

Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), ANI Pharmaceuticals (ANIP) and Theravance Biopharma (TBPH)

TipRanksMay 9, 2023 06:21 ET

SVB Securities Reaffirms Their Buy Rating on Theravance Biopharma (TBPH)

TipRanksMar 3, 2023 00:21 ET

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $19 Price Target

BenzingaFeb 28, 2023 06:15 ET

SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating

MT NewswiresNov 17, 2022 10:15 ET

Theravance Biopharma Analyst Ratings

Benzinga Analyst RatingsNov 17, 2022 06:04 ET

SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14

Benzinga Real-time NewsNov 17, 2022 06:04 ET

Robert W. Baird Reaffirms Their Hold Rating on Theravance Biopharma (TBPH)

TipRanksNov 9, 2022 23:20 ET

HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating

MT NewswiresNov 8, 2022 10:55 ET

Needham Sticks to Its Hold Rating for Theravance Biopharma (TBPH)

TipRanksNov 8, 2022 06:40 ET